Aryl Amide Derivatives for RAF/MEK Complex Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RAF/MEK complex stabilizers and MEK inhibitors are insufficient for effectively treating RAS-mutant cancers, particularly RAS-mutant non-small cell lung cancer, due to less than satisfactory clinical effects from existing compounds like selumetinib and trametinib.
Innovation Solution
Development of aryl amide derivatives with specific chemical structures that stabilize the RAF/MEK complex and inhibit MEK activity, utilizing hydrogen bonding interactions with MEK to enhance inhibitory effects on MEK phosphorylation and cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing MEK inhibitors (selumetinib, trametinib) are used to treat RAS-mutant cancers, then MEK inhibition activity is achieved, but clinical effects are less than satisfactory
Solution Approach 1:
The patent combines two distinct mechanisms into a single compound: MEK inhibition activity and RAF/MEK complex stabilization activity. This dual-action approach addresses the limitation of existing MEK inhibitors by simultaneously blocking MEK signaling and preventing feedback activation through RAF/MEK complex stabilization, thereby improving clinical effectiveness against RAS-mutant cancers
Solution Approach 2:
The invention modifies the chemical structure parameters of MEK inhibitors by introducing specific substituents (e.g., difluoromethyl group at position 3, various aniline groups at position 2) to enhance both MEK inhibition potency and RAF/MEK complex stabilization capability, transforming a single-function inhibitor into a dual-function agent with improved clinical performance
2Reliability
If MEK inhibitors are used alone or in combination with RAF inhibitors, then some clinical effects are observed, but feedback activation of MAPK signaling pathway occurs
Solution Approach 1:
The compound preemptively stabilizes the RAF/MEK complex before feedback activation can occur. By establishing a stable complex between RAF and MEK, the invention prevents the dissociation and reactivation that leads to feedback activation of the MAPK pathway, thereby counteracting the harmful effect before it manifests
Solution Approach 2:
The invention merges MEK inhibition with RAF/MEK complex stabilization in a single molecular entity, eliminating the need for separate combination therapy. This integrated approach simultaneously achieves MEK blockade and prevents feedback activation through complex stabilization, resolving the contradiction between achieving clinical effect and avoiding feedback activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aryl amide derivatives exhibit potent MEK1-inhibiting and BRAF-inhibiting activities, effectively inhibiting the growth of cancer cells with RAS and BRAF mutations, such as HCT-116 and Colo-205 cells.
Implementation Method 1
utilizing hydrogen bonding interactions with MEK to enhance inhibitory effects on MEK phosphorylation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: wherein X1, X2, X3 and X4 are each independently -CR2= or -N=, R2 is, for example, a halogen atom, R1 is, for example, -S(=O)2-NH-R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.